{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:59:53Z","timestamp":1780923593335,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.urolonc.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:46:03Z","timestamp":1778820363000},"page":"225-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-7418","authenticated-orcid":false,"given":"Patricia","family":"Rioja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Passarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Angel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wbeimar","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freya Bosma","family":"Ainaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Anguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Ruiz-Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Plata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn Ignacio","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orta-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda N. Gandur","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ray Manneh Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Sade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2026.04.008_bib0001","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00345-022-03993-6","article-title":"Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group","volume":"41","author":"Diana","year":"2023","journal-title":"World J Urol."},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.008_bib0002","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00345-018-2286-7","article-title":"Epidemiology and screening for renal cancer","volume":"36","author":"Rossi","year":"2018","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.008_bib0003","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.008_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.008_bib0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.008_bib0006","first-page":"107","article-title":"Blueprint for cancer research: critical gaps and opportunities","volume":"71","author":"Elmore","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.urolonc.2026.04.008_bib0007","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2\u2013VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med."},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2026.04.008_bib0008","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2019.37.15_suppl.4508","article-title":"Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): update on Carmena trial with focus on intermediate IMDC-risk population","volume":"37","author":"Mejean","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.04.008_bib0009","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.urolonc.2026.04.008_bib0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.urolonc.2026.04.008_bib0011","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med."},{"issue":"14","key":"10.1016\/j.urolonc.2026.04.008_bib0012","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.urolonc.2026.04.008_bib0013","article-title":"The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma","volume":"23","author":"Nizam","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"34","key":"10.1016\/j.urolonc.2026.04.008_bib0014","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.008_bib0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.euo.2022.07.002","article-title":"Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"5","author":"Pignot","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2026.04.008_bib0016","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.5152\/tud.2021.21006","article-title":"Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma","volume":"47","author":"Van Praet","year":"2021","journal-title":"Turk J Urol"},{"issue":"9286","key":"10.1016\/j.urolonc.2026.04.008_bib0017","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.urolonc.2026.04.008_bib0018","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.008_bib0019","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving Sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.04.008_bib0020","series-title":"EAU Guidelines: Renal Cell Carcinoma","year":"2023"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.008_bib0021","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.008_bib0023","doi-asserted-by":"crossref","first-page":"163","DOI":"10.33696\/immunology.6.202","article-title":"Cytoreductive nephrectomy following immunotherapy: evolution, pearls, and pitfalls of treatment","volume":"6","author":"Davis","year":"2024","journal-title":"J Cell Immunol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.04.008_bib0024","first-page":"217","article-title":"Prognostic factors and treatment outcomes in renal cell carcinoma: a comprehensive analysis","volume":"12","author":"H\u00fccreli","year":"2024","journal-title":"Nam\u0131k Kemal Med J"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.008_bib0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2014.12.036","article-title":"Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma","volume":"67","author":"Gr\u00fcnwald","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.04.008_bib0026","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.euo.2019.12.004","article-title":"Deferred cytoreductive nephrectomy following presurgical vascular endothelial growth factor receptor-targeted therapy in patients with primary metastatic clear cell renal cell carcinoma: a pooled analysis of prospective trial data","volume":"3","author":"de Bruijn","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.04.008_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/oncolo\/oyaf004","article-title":"Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors","volume":"30","author":"do Amaral","year":"2025","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.008_bib0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/iju.15594","article-title":"The role of cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a review of current evidence and ongoing trials","volume":"32","author":"Hara","year":"2025","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.04.008_bib0029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/KCA-210010","article-title":"\u201cPROBE\u201ding the role of cytoreductive nephrectomy in advanced renal cancer","volume":"6","author":"Bell","year":"2022","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.urolonc.2026.04.008_bib30","unstructured":"Study Details | NCT06882486 | Post-immunotherapy nephrectomy for metastatic kidney cancer after complete or major response to systemic therapy | ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06882486."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:04:36Z","timestamp":1780920276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1078143926002188"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}